Laaksonen, Reijo

Biological, clinical and population relevance of 95 loci for blood lipids

Teslovich, T. M., Musunuru, K., Smith, A. V., Edmondson, A. C., Stylianou, I. M., Koseki, M., Pirruccello, J. P., Ripatti, S., Chasman, D. I., Willer, C. J., et al. (2010) · Nature

Genetic Associations and EpidemiologyLipoproteins and Cardiovascular Health

Cited by 3,487

Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease

Cardiogenics, Schunkert, H., the CARDIoGRAM Consortium, König, I. R., Kathiresan, S., Reilly, M. P., Assimes, T. L., Holm, H., Preuss, M., Stewart, A. F. R., et al. (2011) · Nature Genetics

Genetic Associations and EpidemiologyGenetic Mapping and Diversity in Plants and Animals

Cited by 1,866

Large-scale association analysis identifies new risk loci for coronary artery disease

The CARDIoGRAMplusC4D Consortium, Deloukas, P., DIAGRAM Consortium, CARDIOGENICS Consortium, MuTHER Consortium, Wellcome Trust Case Control Consortium, Kanoni, S., Willenborg, C., Farrall, M., Assimes, T. L., et al. (2013) · Nature Genetics

Genetic Associations and EpidemiologyGenetic Mapping and Diversity in Plants and Animals

Cited by 1,614

Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine

Valkonen, V.-P., Päivä, H., Salonen, J. T., Lakka, T. A., Lehtimäki, T., Laakso, J., & Laaksonen, R. (2001) · The Lancet

Nitric Oxide and Endothelin EffectsCancer-related gene regulation

Cited by 562

Phenotype standardization for statin-induced myotoxicity

Alfirevic, A., Neely, D., Armitage, J., Chinoy, H., Cooper, R. G., Laaksonen, R., Carr, D. F., Bloch, K. M., Fahy, J., Hanson, A., et al. (2014) · Clinical Pharmacology & Therapeutics

Lipoproteins and Cardiovascular HealthMuscle and Compartmental Disorders

Cited by 220

FGF21 is a biomarker for mitochondrial translation and mtDNA maintenance disorders

Lehtonen, J. M., Forsström, S., Bottani, E., Viscomi, C., Baris, O. R., Isoniemi, H., Höckerstedt, K., Österlund, P., Hurme, M., Jylhävä, J., et al. (2016) · Neurology

Mitochondrial Function and PathologyFibroblast Growth Factor Research

Cited by 220

Integrative Genomics Reveals Novel Molecular Pathways and Gene Networks for Coronary Artery Disease

Mäkinen, V.-P., Civelek, M., Meng, Q., Zhang, B., Zhu, J., Levian, C., Huan, T., Segrè, A. V., Ghosh, S., Vivar, J., et al. (2014) · PLoS Genetics

Bioinformatics and Genomic NetworksGenetic Associations and Epidemiology

Cited by 196

Susceptibility of low-density lipoprotein particles to aggregate depends on particle lipidome, is modifiable, and associates with future cardiovascular deaths

Ruuth, M., Nguyen, S. D., Vihervaara, T., Hilvo, M., Laajala, T. D., Kondadi, P. K., Gisterå, A., Lähteenmäki, H., Kittilä, T., Huusko, J., et al. (2018) · European Heart Journal

Lipoproteins and Cardiovascular HealthAtherosclerosis and Cardiovascular Diseases

Cited by 180

Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans

Laaksonen, R., Jokelainen, K., Sahi, T., Tikkanen, M. J., & Himberg, J.-J. (1995) · Clinical Pharmacology & Therapeutics

Coenzyme Q10 studies and effectsLipoproteins and Cardiovascular Health

Cited by 177

The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle

Laaksonen, R., Jokelainen, K., Laakso, J., Sahi, T., Härkönen, M., Tikkanen, M. J., & Himberg, J.-J. (1996) · The American Journal of Cardiology

Coenzyme Q10 studies and effectsLipoproteins and Cardiovascular Health

Cited by 171

Decreased skeletal muscle mitochondrial DNA in patients treated with high-dose simvastatin

Schick, B. A., Laaksonen, R., Frohlich, J. J., Päivä, H., Lehtimäki, T., Humphries, K. H., & Côté, H. C. F. (2007) · Clinical Pharmacology & Therapeutics

Mitochondrial Function and PathologyLipoproteins and Cardiovascular Health

Cited by 103

PCSK9 inhibition alters the lipidome of plasma and lipoprotein fractions

Hilvo, M., Simolin, H., Metso, J., Ruuth, M., Öörni, K., Jauhiainen, M., Laaksonen, R., & Baruch, A. (2018) · Atherosclerosis

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 87

Proprotein convertase subtilisin/kexin type 9 (PCSK9) gene is a risk factor of large-vessel atherosclerosis stroke

Abboud, S., Karhunen, P. J., Lütjohann, D., Goebeler, S., Luoto, T., Friedrichs, S., Lehtimaki, T., Pandolfo, M., & Laaksonen, R. (2007) · PLoS ONE

Lipoproteins and Cardiovascular HealthCerebrovascular and Carotid Artery Diseases

Cited by 77

Beyond LDL-C lowering: distinct molecular sphingolipids are good indicators of proprotein convertase subtilisin/kexin type 9 (PCSK9) deficiency

Jänis, M. T., Tarasov, K., Ta, H. X., Suoniemi, M., Ekroos, K., Hurme, R., Lehtimäki, T., Päivä, H., Kleber, M. E., März, W., et al. (2013) · Atherosclerosis

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 41